Join
Live feed
·
PRReleasevia Quantisnow
AngioDynamics Inc. logo

AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

ByQuantisnow·Wall Street's wire, on your screen.
ANGO· AngioDynamics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ANGO (AngioDynamics Inc.) and more on Quantisnow.